PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, includin… Read more
Market Cap & Net Worth: PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (NASDAQ:PDSB) has a market capitalization of $37.76 Million ($37.76 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23186 globally and #8132 in its home market, demonstrating a 0.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PDS Biotechnology Corp's stock price $0.69 by its total outstanding shares 54721307 (54.72 Million).
PDS Biotechnology Corp Market Cap History: 2015 to 2026
PDS Biotechnology Corp's market capitalization history from 2015 to 2026. Data shows change from $13.68 Billion to $37.76 Million (-46.30% CAGR).
Index Memberships
PDS Biotechnology Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #622 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2045 of 3165 |
Weight: PDS Biotechnology Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PDS Biotechnology Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PDS Biotechnology Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PDSB by Market Capitalization
Companies near PDS Biotechnology Corp in the global market cap rankings as of March 18, 2026.
Key companies related to PDS Biotechnology Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PDS Biotechnology Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, PDS Biotechnology Corp's market cap moved from $13.68 Billion to $ 37.76 Million, with a yearly change of -46.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.76 Million | -10.37% |
| 2025 | $42.12 Million | -52.77% |
| 2024 | $89.20 Million | -67.20% |
| 2023 | $271.96 Million | -62.35% |
| 2022 | $722.32 Million | +62.96% |
| 2021 | $443.24 Million | +278.50% |
| 2020 | $117.10 Million | -19.25% |
| 2019 | $145.01 Million | -58.72% |
| 2018 | $351.31 Million | -96.57% |
| 2017 | $10.25 Billion | -25.04% |
| 2016 | $13.68 Billion | 0.00% |
| 2015 | $13.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PDS Biotechnology Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.76 Million USD |
| MoneyControl | $37.76 Million USD |
| MarketWatch | $37.76 Million USD |
| marketcap.company | $37.76 Million USD |
| Reuters | $37.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.